M Diaz-Llopis1, M D Pinazo-Durán2. 1. Unidades de Retina/Mácula y Oftalmología Infantil, Hospital La Fe, Universidad de Valencia, Valencia, España; Unidad de Oftalmo-Biología Celular y Molecular, Departamento de Cirugía. Facultad de Medicina y Odontología, Universidad de Valencia, Valencia, España; Centros de especialidades calle Alboraya y Juan Llorens, Hospital General de Valencia, , Valencia, España; Unidad de Investigación Oftalmológica "Santiago Grisolía"/FISABIO, e Instituto Oftalmológico de Valencia (IOVA). Consellería de Sanitat de la Generalitat Valenciana, Valencia, España; Sociedad Española de Miopía, España; Sociedad de Investigación en Retina y Visión (SIREV), España. Electronic address: manuel.diaz@uv.es. 2. Unidad de Oftalmo-Biología Celular y Molecular, Departamento de Cirugía. Facultad de Medicina y Odontología, Universidad de Valencia, Valencia, España; Unidad de Investigación Oftalmológica "Santiago Grisolía"/FISABIO, e Instituto Oftalmológico de Valencia (IOVA). Consellería de Sanitat de la Generalitat Valenciana, Valencia, España; Sociedad de Investigación en Retina y Visión (SIREV), España.
Abstract
OBJECTIVE: To confirm the clinical security and effectiveness of the daily application of 0.01% superdiluted atropine eyedrops in the progression of myopia in children. MATERIAL AND METHODS: A total of 200 children 9-12 years of age were randomised into a treated group and a control without treatment. Refraction under cycloplegia was performed. RESULTS:Myopia progression of the treated group was -0.14±0.35 versus -0.65±0.54 in the control group without treatment. Only 2% of patients were forced to stop treatment due to side effects. CONCLUSION:Atropine superdilutedatropine 0.01% eyedrops is effective and well tolerated, and reduced myopia progression by 25%.
RCT Entities:
OBJECTIVE: To confirm the clinical security and effectiveness of the daily application of 0.01% superdiluted atropine eyedrops in the progression of myopia in children. MATERIAL AND METHODS: A total of 200 children 9-12 years of age were randomised into a treated group and a control without treatment. Refraction under cycloplegia was performed. RESULTS:Myopia progression of the treated group was -0.14±0.35 versus -0.65±0.54 in the control group without treatment. Only 2% of patients were forced to stop treatment due to side effects. CONCLUSION:Atropine superdiluted atropine 0.01% eyedrops is effective and well tolerated, and reduced myopia progression by 25%.
Authors: Lutz Joachimsen; Navid Farassat; Tim Bleul; Daniel Böhringer; Wolf A Lagrèze; Michael Reich Journal: Int Ophthalmol Date: 2021-02-25 Impact factor: 2.031
Authors: Jeffrey J Walline; Kristina B Lindsley; S Swaroop Vedula; Susan A Cotter; Donald O Mutti; Sueko M Ng; J Daniel Twelker Journal: Cochrane Database Syst Rev Date: 2020-01-13
Authors: Lutz Joachimsen; Daniel Böhringer; Nikolai J Gross; Michael Reich; Julia Stifter; Thomas Reinhard; Wolf A Lagrèze Journal: Ophthalmol Ther Date: 2019-06-12